Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Lithera has received notice of allowance (NOA) from the US Patent and Trademark Office (USPTO) for a patent application covering compositions and methods of use associated with LIPO-102.
Subscribe to our email newsletter
LIPO-102 is Lithera’s novel injectable combination of salmeterol xinafoate (SX) and fluticasone propionate (FP) for selective, non-ablative fat reduction.
LIPO-102 is currently under development for the treatment of symptomatic exophthalmos (protrusion of the eye from the orbit) associated with thyroid-related eye disease (the thyroid condition is also known as Graves’ Disease) and the reduction of abdominal adiposity.
Lithera said that once issued, the patent will afford the company market exclusivity for LIPO-102 into 2028.